What is the difference between alpha and beta defensins?

Alpha-defensins are found mainly in neutrophils and Paneth cells (gut), while beta-defensins are expressed broadly on epithelial surfaces (skin, airways, urogenital tract). They differ in disulphide bond patterns but share similar antimicrobial mechanisms.

Can you take defensin supplements?

No. Defensins are not available as supplements and are not administered therapeutically. Research focuses on supporting natural defensin production through gut health, nutrition, and microbiome management.

How are defensins related to gut health?

Paneth cell alpha-defensins (HD-5 and HD-6) help maintain the intestinal barrier and regulate the microbiome. Reduced defensin levels are linked to ileal Crohn's disease and may contribute to dysbiosis.

Could defensins replace antibiotics?

Synthetic defensin analogues are being developed as potential antimicrobials, but they are not yet available. Their broad-spectrum activity and reduced resistance potential make them promising candidates, but challenges remain with formulation and delivery.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 8 March 2026

Share:X Post LinkedIn

Immune & Inflammatory•Updated 2026-03-08•5 min read

What Is Defensins? Benefits, Research & Safety

A family of antimicrobial peptides forming a crucial part of innate immunity, with activity against bacteria, fungi, and viruses.

Share:X Post LinkedIn

Also known as:

Alpha-Defensins

Beta-Defensins

Human Neutrophil Peptides

HNPs

HBDs

DAnimal/cell evidence onlyUK: Sold as 'research only' (UK)WADA: Sport status unclear

UK summary: Endogenous family of antimicrobial peptides. Synthetic defensin analogues are in early development; not currently a licensed UK medicine for any indication.

Quick Facts

Overview

Defensins are a family of small (29-45 amino acid), cysteine-rich antimicrobial peptides that form a critical component of the innate immune system. They are among the body's first-line defences against microbial pathogens, present on epithelial surfaces, in neutrophils, and in various secretions. Human defensins are classified into two main subfamilies based on their disulphide bond patterns: - **Alpha-defensins (α-defensins):** Six known human α-defensins. HNP-1 through HNP-4 are found in neutrophils; HD-5 and HD-6 are expressed in intestinal Paneth cells. - **Beta-defensins (β-defensins):** Over 30 identified. HBD-1 is constitutively expressed on epithelial surfaces; HBD-2 and HBD-3 are induced by infection and inflammation. Defensins work by disrupting microbial membranes through electrostatic interaction with negatively charged phospholipids. They also modulate adaptive immune responses, acting as chemoattractants for immune cells and linking innate and adaptive immunity. Altered defensin expression has been implicated in various conditions including inflammatory bowel disease (particularly ileal Crohn's disease, where Paneth cell α-defensin levels are reduced), skin infections, respiratory infections, and periodontal disease. Defensins remain primarily research biomarkers and targets rather than therapeutic agents, though synthetic defensin analogues are being developed as potential antimicrobial drugs.

Evidence standards summary

Defensins — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

Endogenous family of antimicrobial peptides. Synthetic defensin analogues are in early development; not currently a licensed UK medicine for any indication.

02Human evidence grade

ETheoretical / insufficientStrength of evidence from published human trials.

03Preclinical evidence grade

BModerate human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Defensins are endogenous peptides, not therapeutic agents. Synthetic analogues remain investigational.
EU: Same—research biomarkers and drug development templates, not approved therapeutics.
Notes: Defensins are studied primarily as biomarkers and as templates for developing new antimicrobial drugs. No defensin-based therapeutics are currently approved. Defensin levels are measured in research settings for various inflammatory and infectious conditions.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Oral defensin supplements boost immunity.
Defensin sprays prevent COVID, flu, and colds.
Topical defensins treat eczema, acne, infections.
Synthetic defensins replace antibiotics.

07Common internet claims

Marketed in wellness supplements as 'immune-boosting peptides'.
Sold by some online retailers as research-only injectable.
Promoted in 'natural antibiotic' positioning by alternative-medicine clinics.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Defensin supplements boost immunity”	E	No	High	Defensins are produced locally and cannot be replaced by oral supplements.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Oral defensins are degraded; supplement safety profile depends on what's actually in the supplement.
Injectable defensin products have no human safety data.
Pro-inflammatory effects at high concentrations.
Theoretical risk of disrupting normal microbiome / immune balance.

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Sold as 'research only' (UK)

Defensins are endogenous peptides, not therapeutic agents. Synthetic analogues remain investigational.

14EU legal position

Same—research biomarkers and drug development templates, not approved therapeutics.

15What this page cannot tell you

Whether any 'defensin supplement' contains intact defensin peptide.
Whether oral / nasal defensin products produce any meaningful effect.
Long-term consequences of exogenous antimicrobial peptide signalling.
Whether they interact with prescribed antibiotics.

16Last reviewed

Last reviewed: 8 March 2026

Next review due: 8 March 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Synthetic defensin development is early-stage; no UK-licensed product.
Pharmacokinetics of any exogenous delivery route in humans absent.
Long-term safety entirely unstudied.

19Safer alternatives / established care pathways

GP and infectious-diseases referral for any genuine recurring infection concern.
Standard NHS antimicrobial stewardship — licensed antibiotics where indicated.
Vaccination programmes — the highest-evidence immune intervention available.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

What licensed treatments exist for the infection concern I'm researching?

Discovery & History

Defensins were first identified in rabbit neutrophils by Robert Lehrer and colleagues in the early 1980s. The term "defensin" was coined to reflect their role in host defence. Human neutrophil peptides (HNP-1, HNP-2, HNP-3) were subsequently isolated and characterised. The discovery of beta-defensins came later, with HBD-1 identified in 1995 from human blood plasma and HBD-2 discovered in 1997 from psoriatic skin. This expanded the understanding of defensins from primarily neutrophil-stored to broadly expressed on epithelial surfaces. Research in the 2000s revealed the immunomodulatory functions of defensins beyond direct antimicrobial killing. Studies showed they acted as chemoattractants for dendritic cells and T cells, bridging innate and adaptive immunity. The connection between defensin deficiency and Crohn's disease was established by Wehkamp and colleagues, who showed reduced Paneth cell alpha-defensin expression in ileal Crohn's disease, suggesting a role in the pathogenesis of inflammatory bowel disease. Synthetic defensin analogues and defensin-inspired antimicrobials continue to be developed as potential treatments for antibiotic-resistant infections.

Mechanism of Action

Defensins exert antimicrobial and immunomodulatory effects through multiple mechanisms: **Membrane Disruption** Primary antimicrobial mechanism: - Electrostatic attraction to negatively charged microbial membranes - Insertion into lipid bilayers - Pore formation and membrane permeabilisation - Loss of microbial membrane integrity and cell death **Selectivity for Microbes** Defensins preferentially target microbial membranes: - Microbial membranes are rich in negatively charged phospholipids - Mammalian cell membranes have predominantly neutral outer leaflets - Cholesterol in mammalian membranes provides additional protection **Intracellular Targets** Beyond membrane disruption: - Inhibition of bacterial cell wall synthesis - Interference with DNA and protein synthesis - Disruption of bacterial enzymatic activity **Immunomodulatory Functions** Bridging innate and adaptive immunity: - Chemoattraction of dendritic cells, T cells, and monocytes - Activation of complement pathways - Induction of pro-inflammatory cytokines - Enhancement of phagocytosis - Promotion of wound healing

Researched Benefits

Based on preclinical and clinical research findings:

1
Broad-spectrum antimicrobial activity (bacteria, fungi, viruses)
2
First-line innate immune defence on epithelial surfaces
3
Immune cell recruitment and activation
4
Potential biomarkers for inflammatory bowel disease
5
Wound healing promotion
6
Antiviral activity against enveloped viruses
7
Research templates for novel antimicrobial drug development

Claim vs Evidence

How popular claims about Defensins stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Defensin supplements boost immunity”	E	No	High	Defensins are produced locally and cannot be replaced by oral supplements.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Not applicable — defensins are endogenous immune peptides
Frequency	N/A
Duration	N/A
Notes	Defensins are not administered therapeutically. Research focuses on understanding their role in disease, using them as biomarkers, and developing synthetic analogues as potential antimicrobials. Supporting natural defensin production through gut health and nutrition is an area of interest.

Administration Routes

Routes studied in research settings (educational only):

Not administered therapeutically (endogenous peptides)
Synthetic analogues in development for topical and systemic use

Half-Life	Stability
Variable; endogenously produced and rapidly metabolised	Highly stable due to disulphide bonds; resistant to proteolysis

Safety Profile & Known Risks

Commonly Reported Side Effects

Not applicable (endogenous peptides)

Rare Risks & Concerns

Excessive defensin production may contribute to inflammation
Alpha-defensins may promote amyloid formation at high concentrations
Potential tissue damage from overactive antimicrobial response

Contraindications

Not administered as a therapeutic agent

UK & EU Regulatory Context

🇬🇧 United Kingdom

Defensins are endogenous peptides, not therapeutic agents. Synthetic analogues remain investigational.

🇪🇺 European Union

Same—research biomarkers and drug development templates, not approved therapeutics.

Defensins are studied primarily as biomarkers and as templates for developing new antimicrobial drugs. No defensin-based therapeutics are currently approved. Defensin levels are measured in research settings for various inflammatory and infectious conditions.

Clinical Studies Summary

Changes in concentrations of cervicovaginal immune mediators across the menstrual cycle: a systematic review and meta-analysis of individual patient data.

Despite the variability of cervicovaginal immune mediator measurements, our meta-analyses show clear and consistent changes during the menstrual cycle. Many immune mediators were lower in the luteal phase, including chemokines, antibodies, matrix metalloproteinases, and several interleukins. Only interleukin-1α and beta-defensins were higher in the luteal phase.

BMC Med. 2022View on PubMed

Defensins of Grasses: A Systematic Review.

We also provide our results on in silico mining of defensin-like sequences in the genomes of all described grass species and discuss their potential functions. The data presented will form the basis for elucidation of the mode of action of grass defensins and high adaptability of grasses to environmental stress and will provide novel potent molecules for practical use in medicine and agriculture.

Biomolecules. 2020View on PubMed

Cationic antimicrobial peptides and periodontal physiopathology: A systematic review.

Data remain inconsistent between the studies for hBDs mainly due to heterogeneity of the results, periodontal disease diagnostic criteria and assaying technique employed. Given their role in innate immunity and their antimicrobial functions, LL-37 and α-defensins may be eligible as periodontal clinical biomarkers and could be an interesting way for therapeutic development.

J Periodontal Res. 2019View on PubMed

Defensins.

The goal is to provide facial plastic surgeons and aesthetic clinicians with a practical, evidence-based overview of defensin therapy and its potential integration into regenerative aesthetic practice. She also is a minority stockholder in Medicell Technologies.

Facial Plast Surg Clin North Am. 2026View on PubMed

Human β-defensins: The multi-functional natural peptide.

This review briefly introduces the biology of human β-defensins, focusing on their multistage structure and diverse functions. It also discusses several heterologous systems for producing human β-defensins, various delivery systems created for these peptides, and patent applications related to their utilization, concluding with a summary of current challenges and potential solutions.

Biochem Pharmacol. 2024View on PubMed

Defensins: defenders of human reproductive health.

Defensins have problems such as poor stability, low bioavailability and difficulties in their synthesis. Therefore, the production of safe, effective and low-cost drugs remains a challenge.

Hum Reprod Update. 2023View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 4

Approved product

1 of 1 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules

PHASE4

Status: Completed · 45 participants · Advanced Dermatology

Conditions: Skin Aging, Photoaging of Skin

No results postedNCT02765763

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Defensins?

Source research-grade Defensins from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Defensins